Intercept Pharmaceuticals Inc
ntercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced that the FLINT trial of obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) has been stopped early for efficacy based on a planned interim analysis showing that the primary endpoint of the trial has been met. FLINT is a multi-center, double-blind, placebo-controlled clinical trial assessing the safety and efficacy of a 25 mg oral dose of OCA administered daily to biopsy-proven adult NASH patients over a 72-week treatment period. The trial has been sponsored and conducted by the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), a part of the National Institutes of Health, at eight leading US academic hepatology centers comprising the NIDDK's NASH clinical research network (CRN).
The decision to stop FLINT has been based on the recommendation of the Data Safety Monitoring Board (DSMB) which reviewed liver biopsy data from before and at the end of the treatment period in approximately half of the 283 randomized patients, in accordance with a planned interim efficacy analysis. This analysis demonstrated that OCA treatment resulted in a highly statistically significant improvement (p=0.0024 on an intention-to-treat [ITT] basis) in the primary histological endpoint, defined as a decrease in the NAFLD Activity Score (NAS) of at least two points with no worsening of fibrosis, as compared to placebo. Those patients who had not yet completed the trial and therefore did not have a second biopsy were treated as non-responders in the ITT analysis. The pre-defined threshold of statistical significance for stopping FLINT was p < 0.0031.
"The unexpected early stopping of FLINT due to OCA meeting the primary endpoint with such high significance is a major milestone," said Mark Pruzanski, M.D., Chief Executive Officer of Intercept. "NASH has grown to epidemic proportions worldwide, having become a leading cause of cirrhosis and liver failure. On its current trajectory, the disease is projected to become the leading indication for liver transplant. We are deeply grateful to the NIDDK and the NASH CRN for their longstanding commitment both to improving our understanding of the disease and to sponsoring ambitious trials like FLINT in their quest to identify novel treatments for patients suffering from NASH."
Intercept will discuss NASH and the FLINT trial during the previously announced conference call and audio webcast scheduled to take place today at 4:30 p.m. ET. The live event will be available on the investor page of the Intercept website at http://ir.interceptpharma.com or by calling (855) 232-3919 (domestic) or (315) 625-6894 (international) five minutes prior to the start time. A replay of the call will be available on the Intercept website approximately two hours after the completion of the call and will be archived for two weeks
http://ih.advfn.com/p.php?pid=nmona&article=60606013
ahhaha Schade
weil Premarket ist jetzt schon über 170$ ;-))))
Optionen
| Boardmail an "einsteger" |
Wertpapier: Intercept Pharmaceutica |
Optionen
| Boardmail an "einsteger" |
Wertpapier: Intercept Pharmaceutica |
HA ha ha!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Optionen
| Boardmail an "stier1981" |
Wertpapier: Intercept Pharmaceutica |
Optionen
| Boardmail an "Andrew6466" |
Wertpapier: Intercept Pharmaceutica |
Optionen
| Boardmail an "M.Minninger" |
Wertpapier: Intercept Pharmaceutica |
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Intercept Pharmaceutica |
Ein PLUS von knapp 87 US Dollar im PRE Market zum Vorabend kann sich sehen lassen, wo soll das heute eigentlich hingehen? 1000 US Dollar? Mal sehen, ob die wirklich spinnen, die Amis!
Optionen
| Boardmail an "Andrew6466" |
Wertpapier: Intercept Pharmaceutica |